These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

3328 related items for PubMed ID: 25400769

  • 1. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX, Qin QH, Yang WP, Mo QG, Wei CY.
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [Abstract] [Full Text] [Related]

  • 2. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
    Yoshioka T, Hosoda M, Yamamoto M, Taguchi K, Hatanaka KC, Takakuwa E, Hatanaka Y, Matsuno Y, Yamashita H.
    Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542
    [Abstract] [Full Text] [Related]

  • 3. Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study.
    Jin X, Jiang YZ, Chen S, Yu KD, Shao ZM, Di GH.
    Oncotarget; 2015 Apr 20; 6(11):9600-11. PubMed ID: 25826079
    [Abstract] [Full Text] [Related]

  • 4. Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer.
    Petit T, Wilt M, Velten M, Rodier JF, Fricker JP, Dufour P, Ghnassia JP.
    Breast Cancer Res Treat; 2010 Nov 20; 124(2):387-91. PubMed ID: 20824324
    [Abstract] [Full Text] [Related]

  • 5. [Immunohistochemical phenotype of breast carcinomas predicts the effectiveness of primary systemic therapy].
    Kulka J, Tokés AM, Tóth AI, Szász AM, Farkas A, Borka K, Járay B, Székely E, Istók R, Lotz G, Madaras L, Korompay A, Harsányi L, László Z, Rusz Z, Molnár BA, Molnár IA, Kenessey I, Szentmártoni G, Székely B, Dank M.
    Magy Onkol; 2009 Dec 20; 53(4):335-43. PubMed ID: 20071305
    [Abstract] [Full Text] [Related]

  • 6. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
    Kawase M, Toyama T, Takahashi S, Sato S, Yoshimoto N, Endo Y, Asano T, Kobayashi S, Fujii Y, Yamashita H.
    Breast Cancer; 2015 May 20; 22(3):308-16. PubMed ID: 23771556
    [Abstract] [Full Text] [Related]

  • 7. Prognostic value of a positive-to-negative change in hormone receptor status after neoadjuvant chemotherapy in patients with hormone receptor-positive breast cancer.
    Chen S, Chen CM, Yu KD, Zhou RJ, Shao ZM.
    Ann Surg Oncol; 2012 Sep 20; 19(9):3002-11. PubMed ID: 22437200
    [Abstract] [Full Text] [Related]

  • 8. Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers.
    Lee HJ, Park IA, Song IH, Kim SB, Jung KH, Ahn JH, Ahn SH, Kim HH, Gong G.
    PLoS One; 2015 Sep 20; 10(9):e0137885. PubMed ID: 26394326
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy.
    von Minckwitz G, Müller BM, Loibl S, Budczies J, Hanusch C, Darb-Esfahani S, Hilfrich J, Weiss E, Huober J, Blohmer JU, du Bois A, Zahm DM, Khandan F, Hoffmann G, Gerber B, Eidtmann H, Fend F, Dietel M, Mehta K, Denkert C.
    J Clin Oncol; 2011 Jun 01; 29(16):2150-7. PubMed ID: 21519019
    [Abstract] [Full Text] [Related]

  • 12. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.
    Miglietta L, Morabito F, Provinciali N, Canobbio L, Meszaros P, Naso C, Murialdo R, Boitano M, Salvi S, Ferrarini M.
    Eur J Surg Oncol; 2013 Oct 01; 39(10):1046-52. PubMed ID: 23890870
    [Abstract] [Full Text] [Related]

  • 13. Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer.
    Matsubara N, Mukai H, Fujii S, Wada N.
    Breast Cancer Res Treat; 2013 Jan 01; 137(1):203-12. PubMed ID: 23184081
    [Abstract] [Full Text] [Related]

  • 14. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
    von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Konecny GE, Denkert C, Nekljudova V, Mehta K, Loibl S.
    J Clin Oncol; 2012 May 20; 30(15):1796-804. PubMed ID: 22508812
    [Abstract] [Full Text] [Related]

  • 15. Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer.
    Jones RL, Salter J, A'Hern R, Nerurkar A, Parton M, Reis-Filho JS, Smith IE, Dowsett M.
    Breast Cancer Res Treat; 2010 Jan 20; 119(2):315-23. PubMed ID: 19247830
    [Abstract] [Full Text] [Related]

  • 16. Progesterone receptor loss identifies luminal-type local advanced breast cancer with poor survival in patients who fail to achieve a pathological complete response to neoadjuvant chemotherapy.
    Chen S, Huang L, Chen CM, Shao ZM.
    Oncotarget; 2015 Jul 20; 6(20):18174-82. PubMed ID: 26053183
    [Abstract] [Full Text] [Related]

  • 17. Predictive value of Ki67 for adjuvant chemotherapy in node-negative, hormone receptor-positive breast cancer.
    Sutepvarnon A, Warnnissorn M, Srimuninnimit V.
    J Med Assoc Thai; 2013 Feb 20; 96 Suppl 2():S60-6. PubMed ID: 23590023
    [Abstract] [Full Text] [Related]

  • 18. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
    Tanioka M, Sasaki M, Shimomura A, Fujishima M, Doi M, Matsuura K, Sakuma T, Yoshimura K, Saeki T, Ohara M, Tsurutani J, Watatani M, Takano T, Kawabata H, Mukai H, Naito Y, Hirokaga K, Takao S, Minami H.
    Breast; 2014 Aug 20; 23(4):466-72. PubMed ID: 24742606
    [Abstract] [Full Text] [Related]

  • 19. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer.
    Ono M, Tsuda H, Shimizu C, Yamamoto S, Shibata T, Yamamoto H, Hirata T, Yonemori K, Ando M, Tamura K, Katsumata N, Kinoshita T, Takiguchi Y, Tanzawa H, Fujiwara Y.
    Breast Cancer Res Treat; 2012 Apr 20; 132(3):793-805. PubMed ID: 21562709
    [Abstract] [Full Text] [Related]

  • 20. Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting.
    Gamucci T, Pizzuti L, Sperduti I, Mentuccia L, Vaccaro A, Moscetti L, Marchetti P, Carbognin L, Michelotti A, Iezzi L, Cassano A, Grassadonia A, Astone A, Botticelli A, Magnolfi E, Di Lauro L, Sergi D, Fuso P, Tinari N, Barba M, Maugeri-Saccà M, Landucci E, Conti F, Sanguineti G, De Tursi M, Iafrate G, Giordano A, Ciliberto G, Natoli C, Vici P.
    J Cell Physiol; 2018 Mar 20; 233(3):2313-2323. PubMed ID: 28710865
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 167.